GSK terminates collaboration agreement with Alector after two drug setbacks
GSK's termination follows failed trials for both progranulin-elevating antibodies developed under the partnership, and Alector separately paid off its outstanding loan.
GSK has moved to end its collaboration with Alector, Inc. over the investigational monoclonal antibodies latozinemab and nivisnebart. On July 6, 2026, GSK provided written notice terminating the Collaboration and License Agreement, with the termination set to take effect 180 days later, on January 2, 2027.1
The partnership had been in place since 2021. Alector had been developing the two progranulin-elevating antibodies with Glaxo Wellcome UK Limited under a Collaboration and License Agreement dated July 1, 2021, later amended on May 19, 2023.1
Both programs hit trouble in trials over the past year. On October 21, 2025, Alector disclosed that the Phase 3 "INFRONT-3" trial of latozinemab in patients with frontotemporal dementia tied to a progranulin gene mutation had failed to reach its clinical co-primary endpoint.1 Then on April 29, 2026, the company said it was stopping the Phase 2 "PROGRESS-AD" trial of nivisnebart in early Alzheimer's disease, a decision made after an interim futility analysis.1
Separately, Alector cleared its debt obligations. On July 8, 2026, the company fully repaid and closed out its Loan and Security Agreement with Hercules Capital, Inc., originally dated November 14, 2024.1 The repayment totaled $10,428,827.77 in principal, along with accrued interest and additional term and prepayment charges.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.